Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma

Blood blood.2024024681.

https://doi.org/10.1182/blood.2024024681

Published: 2024

Includes: Supplemental data

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: Efficacy and Safety Results from the Single Arm Phase 2 Study

Blood (2023) 142 (Supplement 1): 608.

https://doi.org/10.1182/blood-2023-173972

Published: 2023

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Blood (2022) 140 (Supplement 1): 763–765.

https://doi.org/10.1182/blood-2022-156553

Published: 2022

Journal Articles

Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

John M. Burke, Gustavo Fonseca, Wojciech Jurczak, Jason Melear, Miguel Islas-Ohlmayer, James A Reeves, Parameswaran Venugopal, Tomasz Wróbel, Don Stevens, John M. Pagel, Jerome Goldschmidt, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Nilanjan Ghosh

Blood (2021) 138 (Supplement 1): 527.

https://doi.org/10.1182/blood-2021-151054

Published: 2021

Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Blood (2021) 138 (Supplement 1): 2454.

https://doi.org/10.1182/blood-2021-147891

Published: 2021

Journal Articles

Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Ian W. Flinn, David Andorsky, Jason Melear, Sudhir Manda, Bertrand Anz, III, Kathryn Kolibaba, Habte Yimer, John M. Burke, Suzanne Fanning, Jay Courtright, Miguel Islas-Ohlmayer, Suman Kambhampati, Tamas Vizkelety, John Pesko, Brenda Chyla, Dingfeng Jiang, Jeff P. Sharman

Blood (2021) 138 (Supplement 1): 3725.

https://doi.org/10.1182/blood-2021-147258

Published: 2021

Journal Articles

Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study

Ian W. Flinn, MD PhD, David Andorsky, MD PhD, Jason M. Melear, MD, Sudhir Manda, MD, Bertrand M. Anz, III, MD, Kathryn Kolibaba, MD, Habte A. Yimer, MD, John M. Burke, MD, Suzanne R. Fanning, DO, Jay Courtright, MD, Miguel Islas-Ohlmayer, MD, Suman Kambhampati, MD, Daniel Dingfeng Jiang, MD PhD, John C. Pesko, PhD, Tamas Vizkelety, MD, Simon Sharmokh, MPH, PharmD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137406

Published: 2020

Journal Articles

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Jeff P. Sharman, MD, David Andorsky, MD, Jason M. Melear, MD, Sudhir Manda, MD, Bertrand M. Anz, III, MD, Kathryn S. Kolibaba, MD, Habte A Yimer, MD, John M Burke, MD, Suzanne R. Fanning, DO, Jay Courtright, MD, Miguel Islas-Ohlmayer, MD, Suman Kambhampati, MD, Abdullah Al Masud, PhD, Todd Zimmerman, Jacqueline Nielsen, PhD, Tamas Vizkelety, Dingfeng Jiang, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 3042.

https://doi.org/10.1182/blood-2019-127408

Published: 2019

Journal Articles

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas, Paolo Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O’Connor, Neil Josephson, Yinghui Wang, Ranjana Advani

Blood (2018) 132 (1): 40–48.

https://doi.org/10.1182/blood-2017-11-815183

Published: 2018

Includes: Supplemental data

Journal Articles

Comparison of Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation of G-CSF-Stimulated Bone Marrow Versus Non-Stimulated Bone Marrow Versus Peripheral Blood

Ilana Schlam, MD, Samantha Buszek*, MD, Matan R Rothschild, MD, Miguel Islas-Ohlmayer, MD, James Essell

Blood (2017) 130 (Supplement 1): 5493.

https://doi.org/10.1182/blood.V130.Suppl_1.5493.5493

Published: 2017

Journal Articles

Adequate Use of the 4T´s Score As a Primary Screening Tool for Heparin Induced Thrombocytopenia

Ilana Miriam Schlam, MD, Eithan Orlev-Shitrit, MD, Chelsea Beaton, Ping Wang, Charles Glueck, MD, Miguel Islas-Ohlmayer, MD

Blood (2016) 128 (22): 5911.

https://doi.org/10.1182/blood.V128.22.5911.5911

Published: 2016

Journal Articles

Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma

Ann S. LaCasce, MD, Gregory Bociek, Ahmed Sawas, Paolo F. Caimi, MD, Edward Agura, Jeffrey Matous, Stephen Ansell, MD PhD, Howland Crosswell, MD, Miguel Islas-Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero-Torres, Julie Vose, Owen A. O'Connor, MD, Neil Josephson, Ranjana Advani

Blood (2015) 126 (23): 3982.

https://doi.org/10.1182/blood.V126.23.3982.3982

Published: 2015

Journal Articles

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Ann LaCasce, MD, R. Gregory Bociek, MD, Jeffrey Matous, MD, Ahmed Sawas, MD, Paolo Caimi, MD, Stephen M. Ansell, MD PhD, Miguel Islas-Ohlmayer, MD, Eric Cheung, MD, Edward Agura, MD, Caroline Behler, MD, Howland Crosswell, MD, Julie M. Vose, MD MBA, Neil Josephson, MD, Ranjana Advani, MD

Blood (2014) 124 (21): 293.

https://doi.org/10.1182/blood.V124.21.293.293

Published: 2014

Journal Articles

Plerixafor Plus G-CSF Compared to Chemotherapy Plus G-CSF for Mobilization of Autologous CD34+ Cells Resulted in Similar Cost but More Predictable Days of Apheresis and Less Hospitalization.

Paul Shaughnessy, MD, Miguel Islas-Ohlmayer, MD, Julie Murphy, Maureen Hougham, RN, Jill MacPherson, FNP, Kurt Winkler, PharmD, Matthew Silva, PharmD, Michael Steinberg, PharmD, Jeffrey Matous, MD, Sheryl Selvey, PharmD, Michael Maris, MD, Peter A. McSweeney, MD

Blood (2009) 114 (22): 2277.

https://doi.org/10.1182/blood.V114.22.2277.2277

Published: 2009

Journal Articles

Human dendritic cell subsets in NOD/SCID mice engrafted with CD34 + hematopoietic progenitors

A. Karolina Palucka, Joel Gatlin, Jean Philippe Blanck, Michael W. Melkus, Sandra Clayton, Hideki Ueno, Elizabeth T. Kraus, Petra Cravens, Lynda Bennett, Angela Padgett-Thomas, Florentina Marches, Miguel Islas-Ohlmayer, J. Victor Garcia, Jacques Banchereau

Blood (2003) 102 (9): 3302–3310.

https://doi.org/10.1182/blood-2003-02-0384

Published: 2003

NARROW

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: Efficacy and Safety Results from the Single Arm Phase 2 Study

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Comparison of Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation of G-CSF-Stimulated Bone Marrow Versus Non-Stimulated Bone Marrow Versus Peripheral Blood

Adequate Use of the 4T´s Score As a Primary Screening Tool for Heparin Induced Thrombocytopenia

Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Plerixafor Plus G-CSF Compared to Chemotherapy Plus G-CSF for Mobilization of Autologous CD34+ Cells Resulted in Similar Cost but More Predictable Days of Apheresis and Less Hospitalization.

Human dendritic cell subsets in NOD/SCID mice engrafted with CD34 + hematopoietic progenitors

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only